Study #2024-1277
A phase I/II study of IVONESCIMAB in recurrent glioblastoma
MD Anderson Study Status
Enrolling
Treatment Agent
Ivonescimab
Description
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma. The goal of Phase 2 of this clinical research study is to learn if the recommended Phase 2 dose of ivonescimab found in Phase 1 can help to control the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Glioblastoma
Study phase:
Physician name:
Anuj Patel
Department:
Neuro-Oncology
For general questions about clinical trials:
1-844-274-8956
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.